Refanezumab
Refanezumab is a monoclonal antibody designed for the treatment of migraine. It is developed by Teva Pharmaceuticals and is currently in the clinical trial phase. Refanezumab works by blocking the calcitonin gene-related peptide receptor (CGRP), a protein that plays a key role in migraine attacks.
Mechanism of Action[edit | edit source]
Refanezumab is a monoclonal antibody that targets and blocks the CGRP receptor. CGRP is a neuropeptide that is released during a migraine attack and is believed to play a key role in the transmission of pain. By blocking the CGRP receptor, refanezumab prevents the activation of this pathway and reduces the frequency and severity of migraine attacks.
Clinical Trials[edit | edit source]
Refanezumab is currently in Phase III clinical trials. In a Phase IIb study, refanezumab demonstrated a significant reduction in the number of migraine days per month compared to placebo. The most common side effects reported were injection site reactions.
Development[edit | edit source]
Refanezumab is being developed by Teva Pharmaceuticals, a global pharmaceutical company specializing in the development, production, and marketing of generic and proprietary branded pharmaceuticals.
See Also[edit | edit source]
- Monoclonal antibodies
- Migraine
- Teva Pharmaceuticals
- Clinical trial
- Calcitonin gene-related peptide receptor
Refanezumab Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD